Characterization of TEC kinase small molecule compounds

Peripheral T-cell lymphoma (PTCL) is a type of blood cancer with poor treatment outcomes, as patients often relapse or do not respond to available therapies. A key factor driving the growth of cancerous T cells in PTCL is a protein called ITK, which helps these cells survive by activating biological pathways that boost cell growth and survival. Our project focuses on developing new treatments by targeting a specific part of the ITK protein called the PHTH domain, which is essential for ITK to function. Current drugs that target ITK usually aim at the protein’s active site, but they often cause unwanted side effects or lose effectiveness over time. Instead, we’re exploring a different approach by finding molecules that can bind to the PHTH domain, preventing ITK from working and stopping the growth of cancer cells.

Using advanced screening technology, we will identify potential molecules that interfere with ITK at the PHTH domain. We will then test these molecules to understand how they work and evaluate their potential as treatments in PTCL models. Additionally, we will investigate whether combining these molecules with other drugs that trigger cell death (called BH3-mimetics) could make the treatment more effective. This research could lead to new, more precise treatments for PTCL, addressing a significant need for better therapies.

Faculty Supervisor:

David W Andrews

Student:

Partner:

ImmVue Therapeutics

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

University of Toronto

Program: